Zhiyi Pharmaceutics
Guangzhou
About Zhiyi Pharmaceutics
Founded in 2013, Zhiyi Bio focuses on the research and development of second-generation probiotics and Live Biotherapeutics. Based on the discovery of strains and drug development with independent intellectual property rights, a lot of innovative research has been carried out, and the “Know-How” from strains to drugs has been established, and the innovative live bacteria drug SK08 is about to enter the clinic. On this basis, Zhiyi will continue to strengthen the research and development of the relationship between human microbiome and disease, including microbial culture group and pathobionts research, target determination and separation of new functional strains.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Total funding: $82.7M
- Funding stage: Late Stage Venture
- Last round: Series C (Mar 2024)
- Website: zypharm.com.cn
- Phone: 020-82258826
Industries & Categories
Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/zhiyi-pharmaceutics-76242 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.